⌕
Elicio Therapeutics · ELTX · Nasdaq
Tenet 44 · Weak
Compare
$1.50−5.66%At closeTenet 44 · Weak
$1.50−0.09 (−5.66%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

Elicio Therapeutics (ELTX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue history is too short to read a growth trend (through FY21), net margin −192.8%. Worth your attention in FY25: Share count (+442.1%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▲23.8%
−39.6
FY21→FY25CAGR —
Free cash flow ($M)▲0.5%
−37.0
FY21→FY25CAGR —
Diluted EPS▲39.3%
−2.58
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+442.1%

2.8mn → 15.3mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$16.0K

−81.6% YoY in FY25.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS−24.9R&D−12.8SG&A−37.7Op income−1.9Tax & other−39.6Net income

Margin trend · direction beats level Gross Operating Net
1007550250%FY21FY25

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.5824, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—0.00.00.00.028,312.0——
Cost of revenue
—0.00.00.00.0433.0——
Gross profit
—————27,879.0——
Research & development
23,537.024,903.033,656.023,849.018,103.048,698.0▼26.0%−15.4%
Selling, general & admin
14,788.012,811.011,330.011,896.05,630.018,488.0▲13.1%−8.8%
Total operating expenses
38,325.037,714.044,986.035,745.023,733.067,186.0▼16.2%−13.4%
Operating incomefeeds ROC rank
−38,325.0−37,714.0−44,986.0−35,745.0−23,733.0−39,307.0▲16.2%—
Other income, net
2,643.0−1,857.0−6,912.0550.0−4,475.0−15,266.0——
Pretax income
−35,682.0−39,571.0−51,898.0−35,195.0−28,208.0−54,573.0▲23.8%—
Income tax
—0.00.00.0————
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−35,737.0−39,571.0−51,898.0−35,195.0−28,208.0−54,573.0▲23.8%—
Per share
Diluted EPSbuyback-sensitive
—−2.58−4.25−6.96−12.90−19.30▲39.3%—
Diluted shares (mn)
—15.3112.205.063.002.82▲25.5%+52.6%
Margins
Gross margin
—————98.5%——
Operating margin
—————−138.8%——
Net margin19th pct in Healthcare
—————−192.8%——
† TTM = trailing four quarters through 2026-09-30.
FY12 – FY20 · 5 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-12 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.